160 related articles for article (PubMed ID: 31540244)
1. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.
Bougen-Zhukov N; Nouri Y; Godwin T; Taylor M; Hakkaart C; Single A; Brew T; Permina E; Chen A; Black MA; Guilford P
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540244
[TBL] [Abstract][Full Text] [Related]
2. E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib.
Bougen-Zhukov N; Decourtye-Espiard L; Mitchell W; Redpath K; Perkinson J; Godwin T; Black MA; Guilford P
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406381
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
Godwin TD; Kelly ST; Brew TP; Bougen-Zhukov NM; Single AB; Chen A; Stylianou CE; Harris LD; Currie SK; Telford BJ; Beetham HG; Evans GB; Black MA; Guilford PJ
Gastric Cancer; 2019 Mar; 22(2):273-286. PubMed ID: 30066183
[TBL] [Abstract][Full Text] [Related]
4. E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors.
Decourtye-Espiard L; Bougen-Zhukov N; Godwin T; Brew T; Schulpen E; Black MA; Guilford P
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008338
[TBL] [Abstract][Full Text] [Related]
5. Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking.
Brew T; Bougen-Zhukov N; Mitchell W; Decourtye L; Schulpen E; Nouri Y; Godwin T; Guilford P
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008266
[TBL] [Abstract][Full Text] [Related]
6. Merging perspectives: genotype-directed molecular therapy for hereditary diffuse gastric cancer (HDGC) and E-cadherin-EGFR crosstalk.
Li D; Lo W; Rudloff U
Clin Transl Med; 2018 Feb; 7(1):7. PubMed ID: 29468433
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Chen I; Mathews-Greiner L; Li D; Abisoye-Ogunniyan A; Ray S; Bian Y; Shukla V; Zhang X; Guha R; Thomas C; Gryder B; Zacharia A; Beane JD; Ravichandran S; Ferrer M; Rudloff U
J Transl Med; 2017 May; 15(1):92. PubMed ID: 28460635
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.
Telford BJ; Chen A; Beetham H; Frick J; Brew TP; Gould CM; Single A; Godwin T; Simpson KJ; Guilford P
Mol Cancer Ther; 2015 May; 14(5):1213-23. PubMed ID: 25777964
[TBL] [Abstract][Full Text] [Related]
9. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
Beetham H; Chen A; Telford BJ; Single A; Jarman KE; Lackovic K; Luxenburger A; Guilford P
Sci Rep; 2019 Aug; 9(1):12511. PubMed ID: 31467357
[TBL] [Abstract][Full Text] [Related]
10. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.
Luxenburger A; Bougen-Zhukov N; Fraser MG; Beetham H; Harris LD; Schmidt D; Cameron SA; Guilford PJ; Evans GB
J Med Chem; 2021 Dec; 64(24):18114-18142. PubMed ID: 34878770
[TBL] [Abstract][Full Text] [Related]
11. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice.
Graziano F; Humar B; Guilford P
Ann Oncol; 2003 Dec; 14(12):1705-13. PubMed ID: 14630673
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
[TBL] [Abstract][Full Text] [Related]
13. CDH1 Gene and Hereditary Diffuse Gastric Cancer Syndrome: Molecular and Histological Alterations and Implications for Diagnosis And Treatment.
Luo W; Fedda F; Lynch P; Tan D
Front Pharmacol; 2018; 9():1421. PubMed ID: 30568591
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Epigenetic Alterations of
Tedaldi G; Molinari C; São José C; Barbosa-Matos R; André A; Danesi R; Arcangeli V; Ravegnani M; Saragoni L; Morgagni P; Rebuzzi F; Canale M; Pignatta S; Ferracci E; Martinelli G; Ranzani GN; Oliveira C; Calistri D; Ulivi P
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34066170
[TBL] [Abstract][Full Text] [Related]
15. Gastric cancer: new genetic developments.
Lynch HT; Grady W; Suriano G; Huntsman D
J Surg Oncol; 2005 Jun; 90(3):114-33; discussion 133. PubMed ID: 15895459
[TBL] [Abstract][Full Text] [Related]
16. [From gene to disease; E-cadherin and hereditary diffuse gastric cancer].
de Bruin JH; Ligtenberg MJ; Nagengast FM; van Krieken JH
Ned Tijdschr Geneeskd; 2003 Dec; 147(50):2474-7. PubMed ID: 14708213
[TBL] [Abstract][Full Text] [Related]
17. Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer.
Huynh JM; Laukaitis CM
Mol Genet Genomic Med; 2016 Mar; 4(2):232-6. PubMed ID: 27064202
[TBL] [Abstract][Full Text] [Related]
18. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.
Brooks-Wilson AR; Kaurah P; Suriano G; Leach S; Senz J; Grehan N; Butterfield YS; Jeyes J; Schinas J; Bacani J; Kelsey M; Ferreira P; MacGillivray B; MacLeod P; Micek M; Ford J; Foulkes W; Australie K; Greenberg C; LaPointe M; Gilpin C; Nikkel S; Gilchrist D; Hughes R; Jackson CE; Monaghan KG; Oliveira MJ; Seruca R; Gallinger S; Caldas C; Huntsman D
J Med Genet; 2004 Jul; 41(7):508-17. PubMed ID: 15235021
[TBL] [Abstract][Full Text] [Related]
19. Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer.
Abou Khouzam R; Molinari C; Salvi S; Marabelli M; Molinaro V; Orioli D; Saragoni L; Morgagni P; Calistri D; Ranzani GN
Oncotarget; 2017 Mar; 8(12):18811-18820. PubMed ID: 27861150
[TBL] [Abstract][Full Text] [Related]
20. Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature.
Obermair F; Rammer M; Burghofer J; Malli T; Schossig A; Wimmer K; Kranewitter W; Mayrbaeurl B; Duba HC; Webersinke G
Fam Cancer; 2019 Apr; 18(2):253-260. PubMed ID: 30306390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
